As a polyphosphate-binding agent, Sevelamer binds uremic toxins, and studies have shown that CKD patients who took Sevelamer for 3 months had significantly lower C-reactive protein, glycated haemoglobin, and LDL levels, and significantly higher HDL levels compared to the control group (who did not take Sevelamer), suggesting that Sevelamer may ameliorate inflammation and dyslipidaemia and may have some therapeutic efficacy in CKD patients [183]. This evidence concerns the gene CRP and chronic kidney disease.